---
title: "Science and Technology Innovation Medical ETF Huaxia (588130) has seen continuous net capital inflows for 8 consecutive days, with cumulative inflows exceeding 360 million yuan in July."
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/43104521.md"
description: "Data shows that as of July 30, the Science and Technology Innovation Board Healthcare ETF Huaxia (588130) has achieved net capital inflows for 8 consecutive trading days, with cumulative inflows exceeding 360 million RMB in July, indicating sustained investor interest. The average daily turnover over the past month has exceeded 63 million RMB, reflecting active trading and good liquidity. The industrial logic of continuous strengthening global competitiveness of Chinese innovative drugs, driven by policy support, overseas expansion, and the realization of commercial profitability, remains unchanged. Industrial Securities (6.110, 0.02, 0.33%) believes..."
datetime: "2026-07-31T03:02:43.000Z"
locales:
  - [en](https://longbridge.com/en/topics/43104521.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/43104521.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/43104521.md)
author: "[同壁财经](https://longbridge.com/en/profiles/26505347.md)"
---

# Science and Technology Innovation Medical ETF Huaxia (588130) has seen continuous net capital inflows for 8 consecutive days, with cumulative inflows exceeding 360 million yuan in July.

Data shows that as of July 30, the Huaxia Science and Technology Innovation Board Medicine ETF (588130) has achieved net capital inflows for 8 consecutive trading days, with cumulative inflows exceeding 360 million RMB in July, indicating sustained investor interest. The average daily turnover over the past month has exceeded 63 million RMB, reflecting active trading and good liquidity.

The global competitiveness of China's innovative drugs continues to strengthen, driven by policy support, overseas expansion, and the realization of commercial profitability—a core industry logic that remains unchanged. Dongxing Securities Co., Ltd. (6.110, 0.02, 0.33%) believes that "innovation + internationalization" will remain the main theme for the pharmaceutical sector in 2026. Business Development (BD) remains the preferred path for domestic companies to accelerate globalization, with an increasing number of Co-Co models, demonstrating enhanced R&D capabilities and bargaining power of Chinese enterprises. Overseas major pharmaceutical companies face patent cliffs and needs for pipeline replenishment. Coupled with the efficiency and cost advantages of China's innovative drug R&D, the high prosperity of going global is expected to continue.

The Huaxia Science and Technology Innovation Board Medicine ETF (588130) provides a convenient tool for low-threshold, one-click exposure to the Sci-Tech Innovation Board medicine sector. It tracks the SSE Science and Technology Innovation Board Biopharmaceutical Index, where the 20% price limit on the Sci-Tech Innovation Board offers high elasticity. The index is highly concentrated in three core tracks: chemical pharmaceuticals, medical devices, and biological products, accounting for over 91% of the total weight, helping ordinary investors seize long-term development opportunities in the innovative drug and device sector. (Off-exchange feeder A: 027142; Feeder C: 027143).

### Related Stocks

- [399441.CN](https://longbridge.com/en/quote/399441.CN.md)
- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [601377.CN](https://longbridge.com/en/quote/601377.CN.md)